Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Completed 4Terminated 2Unknown 1

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 3Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × valrubicin × Clear all
NCT00003129 2023-06-22

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
75 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT01606345 2016-04-22

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
4 enrolled
Genitourinary

Carcinoma, Transitional Cell, Neoplasms

NCT01316874 2015-06-12

Bladder Cancer

Endo Pharmaceuticals

Phase 2/3 Completed
90 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT00003759 2013-01-31

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡